TARSUS PHARMACEUTICALS, INC. (TARS) Return on equity 2020–2025
TARSUS PHARMACEUTICALS, INC. (TARS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-19.3%FY2025 · since FY2020: -16.2% → -19.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -19.3% | +32.1 pp |
| FY2024 | -51.5% | +17.5 pp |
| FY2023 | -69.0% | -36.8 pp |
| FY2022 | -32.2% | -23.9 pp |
| FY2021 | -8.3% | +7.9 pp |
| FY2020 | -16.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice